![[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care](https://imgproxy.divecdn.com/5lAJkli_KcGt1FSsw4EaegjgP76IHREqYEWbhNBJOXw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlXzEzNDZfeF83MjlfQXJ0d29yay5qcGc=.webp)
.jpg)
German cancer antibody biotech eyes SPAC as route to Nasdaq
Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special purpose acquisition company (SPAC) model to hop onto the Nasdaq.
Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special purpose acquisition company (SPAC) model to hop onto the Nasdaq.
